Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
300 results about "Drug withdrawal" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Drug withdrawal is the group of symptoms that occur upon the abrupt discontinuation or decrease in intake of medications or recreational drugs. In order for the symptoms of withdrawal to occur, one must have first developed a form of drug dependence. This may occur as physical dependence, psychological dependence or both. Drug dependence develops from consuming one or more substances over a period of time. Dependence arises in a dose-dependent manner and produces withdrawal symptoms that vary with the type of drug that is consumed.
Inhibitors of glutaminyl cyclase
The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
Owner:VIVORYON THERAPEUTICS NV
System for monitoring and traceably managing organic livestock growth, slaughter and distribution process
InactiveCN106204061ASlaughter preventionRealize fine feedingLogisticsCommerceDrug withdrawalDrug additive
The invention discloses a system for monitoring and traceably managing an organic livestock growth, slaughter and distribution process. The system, based on Internet of things technology, can help breeding enterprises establish perfect production files, establish data base of meat product traceability, manage safety production, and establish epidemic prevention records; helps a government supervision department achieve livestock production process supervision and control. In addition, being capable of monitoring prohibited veterinary drugs, drug additives, drug withdrawal period in real time, the system can help users avoid the use of prohibited veterinary drugs to prevent livestock slaughter in the withdrawal period and improve animal safety so as to guarantee people's health and life safety, to monitor a animal growth process and achieve fresh meat product traceability, to ensure organic and healthy ecological meat. Further, the system raises the economic benefits of farming enterprises so as to guarantee the profits of the consumers, the breeding enterprises and the government supervision department.
Owner:CHUZHOU UNIV
Novel inhibitors of glutaminyl cyclase
ActiveUS20050215573A1Facilitated DiffusionOrganic active ingredientsBiocideHuntingtons choreaDrug withdrawal
The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
Owner:VIVORYON THERAPEUTICS NV
Neuroprotective synergy of erythropoietin and insulin-like growth factor
InactiveUS20040092444A1Prevention and reduction of severityBiocideSenses disorderInsulin-like growth factorHuntingtons chorea
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.
Owner:BURNHAM INST FOR MEDICAL RES +1
Method and device for treating headaches, sinus congestion and congestion as well as drug withdrawal
InactiveUS6158439ARelieving the patient's ailmentConvenient treatmentDiagnosticsSurgeryDiseaseSinus congestion
A vibrational instrument which is therapeutically beneficial in treating the person suffering from afflictions such as headache, sinus congestion and pressure, and withdrawal due to drug dependency includes a member capable of transmitting vibrational waves through the teeth, jaw and sinus tissue for disposal between teeth of the person. A method of treatment is also provided.
Owner:STREETMAN FOY
Neuroprotective synergy of erythropoietin and insulin-like growth factors
InactiveUS7439063B2Prevention and reduction of severityBiocideSenses disorderInsulin-like growth factorHuntingtons chorea
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.
Owner:BURNHAM INST FOR MEDICAL RES +1
Traditional Chinese medicine composition for treating subacute thyroiditis and preparation method thereof
ActiveCN103099902AImprove clinical symptoms and signsLow recurrence rateAntiviralsUnknown materialsDrug withdrawalClinical study
The invention discloses a traditional Chinese medicine composition for treating subacute thyroiditis. The composition is a preparation prepared from the following raw materials by weight: 15-30 parts of hedyotis diffusa, 9-15 parts of honeysuckle, 15-30 parts of dandelion, 15-30 parts of Chinese violet, 9-15 parts of root of common peony, 9-15 parts of radix scrophulariae, 9-15 parts of peach kernel, 9-15 parts of baked turtle shell and 15-30 parts of sweet wormwood. According to clinical study on the treatment of subacute thyroiditis, the traditional Chinese medicine composition provided by the invention has total effective rate of 93.34%, which is significantly better than 73.33% of a prednisone group, and can effectively reduce erythrocyte sedimentation rate and CRP of subacute thyroiditis patients, and effectively improve clinical symptoms of the patients; although the cooling time, improvement time of neck pain and regression time of neck tenderness are longer than those of the prednisone group, the goiter or nodule disappearance time shows no obvious difference from those of the prednisone group; relapse rate after drug withdrawal is 3.33%, which is significantly lower than 20% of the prednisone group; and the composition has little adverse reaction, which is significantly lower than that of the prednisone group. The invention also discloses a preparation method of the traditional Chinese medicine composition granules.
Owner:LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Novel application of imatinib and derivative thereof to preparation of drugs for treating drug addiction
ActiveCN106074555ALow costImprove bioavailabilityOrganic active ingredientsNervous disorderDrug withdrawalTherapy drug addiction
The invention discloses novel application of imatinib and a derivative thereof and provides novel application of imatinib and the derivative thereof to preparation of drugs for preventing and / or treating drug addiction and preparation of drugs for preventing and / or treating relapse after drug withdrawal. According to the novel application, a classic rat sensitization and conditioned place preference animal model for evaluating addiction is adopted, the influences of imatinib and the derivative methanesulfonic acid imatinib on expression of the recrudescence behavior and sensitization behavior appearing after withdrawal of the conditioned place preference of a rat is formed are observed respectively, and the result indicates that imatinib and the derivative methanesulfonic acid imatinib have an inhibitory effect on morphine addiction and have the effect of preventing relapse after withdrawal of morphine addiction.
Owner:安徽安迪克莱斯医药有限责任公司
Neuroprotective synergy of erythropoietin and insulin-like growth factors
InactiveUS20050197284A9Prevention and reduction of severityBiocideSenses disorderInsulin-like growth factorNervous system
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.
Owner:BURNHAM INST FOR MEDICAL RES +1
Traditional Chinese medicine for treating hypertension
InactiveCN102940730ALower blood pressureGood curative effectCardiovascular disorderMolluscs material medical ingredientsDrug withdrawalApocynum venetum
The invention relates to a traditional Chinese medicine for treating hypertension. The traditional Chinese medicine is characterized by being prepared from the following traditional Chinese medicine raw medicinal materials in parts by weight: 2-15 parts of apocynum venetum, 2-20 parts of wild chrysanthemum flower, 10-30 parts of haw, 2-10 parts of selfheal spike, 3-10 parts of perilla frutescens, 3-15 parts of hooked uncaria, 6-15 parts of medlar, 3-10 parts of abalone shell and 6-15 parts of eucommia bark. The traditional Chinese medicine for treating the hypertension has the advantages that the blood pressure of patients can be reduced in a short time in a manner that the patients take the medicine, the curative effect is stable, the blood pressure cannot be immediately restored to a high-pressure level once drug withdrawal occurs, the preparation method is simple, and the cost is low.
Owner:XIAN FUAN INNOVATION CONSULTATION
Method and kit for detecting HBV PgRNA in blood of patient with hepatitis b and application thereof
InactiveCN105907891AEasy to useHigh detection sensitivityMicrobiological testing/measurementMicroorganism based processesGuidelineDrug withdrawal
The invention discloses a method for detecting HBV PgRNA in blood of a patient with hepatitis b. After pgRNA is extracted, the extracted HBV pgRNA is purified by RNase-free Dnase I; and quantitative determination on pgRNA is achieved by adopting the qRT-PCR method. The invention further provides a kit for detecting the HBV PgRNA in blood of the patient with hepatitis b. The method has the following effects: firstly, the method adopts blood detection, is noninvasive, is normal and is capable of being applied on a large scale; secondly, PgRNA with ultralow carrying capacity in the blood can be detected; and thirdly, the kit and the application thereof in predicating NA drug withdrawal can be used for researching the shape of Chinese PgRNA shape, so that fundamental research data is provided for developing a PgRNA drug. A scheme is provided for solving the problem of finding clinical criteria and a biological marker for predicating NA drug withdrawal, which is one of ten to-be-solved problems of hepatitis B clinical guideline.
Owner:北京旌准医疗科技有限公司
Nasal formulations of benzodiazepine
InactiveUS20140128379A1Non-irritating to the nasal mucosaBiocideOrganic non-active ingredientsBenzodiazepineDrug withdrawal
Owner:CPEX PHARMACEUTICALS INC
N-substituted imidazole carboxylate compound, preparation method and use thereof
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Method for quantitatively detecting TRAb plate-type fluorescent enzyme immunity and application thereof
InactiveCN101692085AConvenient sourceLow priceReceptors for hormonesFluorescence/phosphorescenceAntigenDrug withdrawal
The invention relates to a method for quantitatively detecting TRAb plate-type fluorescent enzyme immunity and an application thereof. The method is characterized in that recombination human thyroxin stimulating hormone receptor (hTSHR) extracellular domain amino terminal proteins is taken as antigen to coat a perforated plate and then is sealed by PBST containing 1-5% of BSA; anti-hTSHR first antibody or standard substance, enzyme-labeled second antibody, fluorescent substrate and stopping solution are sequentially added by utilizing the perforated plate as a carrier; and finally fluorescence intensity is measured on a fluorescence illuminant analyzer. The clinical detection of TRAb which mainly comprises TSAb in patient serum has great significance on pathogenic diagnosis, curative effect observation and drug withdrawal occasion determination of GD hyperthyroidism. The invention performs the fluorescence enzyme immunoassay by utilizing a multi-hole site plastic plate as a solid carrier, has easy sheet material source, low cost and easy promotion, and the method is distinctive, sensitive, accurate and stable, thereby being suitable for clinical requirement and promotion.
Owner:GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Blood-glucose-reducing composition and preparation method thereof
ActiveCN103933346AGood synergyImprove balanceMetabolism disorderPlant ingredientsDrug withdrawalSide effect
The invention discloses a composition which is formed by combining plant materials and has functions of nourishing yin and reducing blood glucose, and a preparation method of the composition. The blood-glucose-reducing composition comprises cortex lycii radicis, fruit of Chinese wolfberry, glossy privet fruit, radix polygonati officinalis, Chinese yam, radix ophiopogonis and semen cassia; the yin-nourishing and blood glucose-reducing composition disclosed by the invention can be prepared into any normal internally-taken dosage form, is remarkable in curative effect for treating and preventing diabetes mellitus, and has total effective rate of over 90% for diabetes mellitus; moreover, after drug withdrawal, the impaired fasting glucose or blood glucose does not rebound two hours after the meal. The yin-nourishing and blood-glucose-reducing composition disclosed by the invention is small in side effect, has effects of tonifying spleen and reinforcing the kidneys, nourishing yin and tonifying yang, mediating internal organs and the like, treats both symptoms and root causes; after entering the body, the drug can promote islet cells to reproduce, can strengthen secretion of insulin, can improve glucose metabolism in the body, and has good prevention and treatment effect on various syndromes caused by diabetes.
Owner:苏庆文
Acne gel containing traditional Chinese medicine components and preparation method thereof
InactiveCN107334845AEasy to useNot easy to relapseAmphibian material medical ingredientsOrganic active ingredientsNepetaSolvent
The present invention provides an acne gel containing traditional Chinese medicine components, the acne gel containing the traditional Chinese medicine components comprises the following active ingredients by weight: 250-1000 parts of acne treatment traditional Chinese medicine extract, 5-8 parts of sulfur, 3-5 parts of venenum bufonis, 5-15 parts of vitamin B6, 1-5 parts of vitamin C glucoside, 5-10 parts of zinc chloride, 0.5-1 part of Allantoin, 0.5-1%wt of an excipient, 0.05-0.15%wt of a surfactant, 0-1%wt of a preservative and 5-10%wt of a solvent; the acne treatment traditional Chinese medicine extract comprises the following raw materials by weight: 30-50 parts of Coptis chinensis, 40-50 parts of Scutellaria baicalensis, 40-50 parts of herba schizonepetae, 30-50 parts of fructus forsythiae, 40-50 parts of radices sileris, 30-50 parts of Fructus Gardeniae, 40-50 parts of immature bitter orange, 50-100 parts of radix sophorae flavescentis, 100-200 parts of dandelion, 30-40 parts of calendula officinalis, 20-30 parts of Tribulus terrestris, 40-50 parts of radix angelicae, 40-50 parts of radix paeoniae alba, 40-50 parts of Poria cocos and 20-40 parts of licorice. The acne gel containing the traditional Chinese medicine components does not contain hormones and antibiotics, and is safer to use, after drug withdrawal, acnes are not easy to recur, and the acne gel containing the traditional Chinese medicine components has the advantages of anti-inflammatory, antipruritic and detoxification effects, long duration and few toxic and side effect, and can also complement skin nutrition, improve the antioxidant capacity of the skin, promote skin healing and eliminate pockmarks.
Owner:SHANDONG ACAD OF CHINESE MEDICINE
Pharmaceutical composition using liensinine to work in coordination with doxorubicin for chemotherapy and application method of pharmaceutical composition
InactiveCN104586870AGood effectInhibition of killingOrganic active ingredientsAntineoplastic agentsDrug withdrawalTherapeutic effect
The invention relates to a pharmaceutical composition using liensinine to work in coordination with doxorubicin for chemotherapy and an application method of the pharmaceutical composition. The pharmaceutical composition comprises a liensinine injection solution and a chemotherapy drug doxorubicin injection solution. The application method comprises the following steps: (1) performing intravenous injection of liensinine once daily according to the dose that actual dosage in the liensinine injection solution to the body weight of a patient is equal to 4.88mg / kg; (2) performing intravenous injection of doxorubicin once according to the dose that the actual dosage in the doxorubicin injection solution to the body weight of the patient is equal to 0.16mg / kg on the day of injecting liensinine according to the step (1); (3) performing intravenous injection of the doxorubicin injection solution once again according to the dose in the step (2) on the sixth day; and (4) determining whether to circulate according to the method of the steps (1)-(3) or not, the number of circulation times and the intermediate drug withdrawal time from the eleventh day according to the bearing capacity and the treatment effect of a patient body. Compared with the prior art, in the aspect of inhibiting and killing various malignant tumor cells, the pharmaceutical composition provided by the invention has the advantages of reducing the dosage, shortening the treatment period and reducing the occurrence of toxic and side reactions.
Owner:ARMY MEDICAL UNIV
Beverage for relieving with drawal syndrome for druggy recovery period
The present invention relates to a beverage for relieving anxious syndrome of drug withdrawal man in the stage of recovery with obvious effect. The beverage contains 5 ml-200ml / L of aqueous extract of Baihuarong (a Chinese kerbal medicine).
Owner:王红红
Internet-based patients' medicine taking intervention method
InactiveCN107978375ARealize daily medication reminderCheck in timeDrug referencesDiseaseDrug withdrawal
Owner:HARBIN GUANGKAI TECH DEV
Pharmaceutical composition for easing pain and preparation method thereof
The invention discloses a pharmaceutical composition for easing pain and a preparation method of the pharmaceutical composition. The active ingredient of the pharmaceutical composition comprises water extract of Thalictrum trichopus Franch, wherein Thalictrum trichopus Franch refers to dried roots of plant in ranunculaceae thalictrum. The pharmaceutical composition can take pain easing effect quickly and hardly causes side effect; patients can take the pharmaceutical composition under the simple guidance of medical personnel; the pain easing effect fast disappear after drug withdrawal, and therefore the disease syndromes cannot be covered; and the pharmaceutical composition can be used for easing clinical acute pain, cancer pain and pre-hospital care pain of the children and adults.
Owner:赵明强
Medicine for treating cough variant asthma and preparation method of medicine
ActiveCN102698168AGreat tasteImprove immunityAnthropod material medical ingredientsRespiratory disorderSmoked PlumDrug withdrawal
The invention discloses a medicine for treating cough variant asthma. The medicine comprises 8-12 parts of momordica grosvenori, 4-8 parts of radix polygonati officinalis, 9-15 parts of radix astragali preparata, 3-7 parts of indigo naturalis, 4-8 parts of blackberry lily, 4-8 parts of rhizoma pinellinae praeparata, 4-8 parts of radix stemonae, 6-12 parts of tussilago farfara, 4-8 parts of aster,0.8-1.2 parts of as arum, 8-12 parts of earthworm, 7-11 parts of radices stellariae dichotomae, 8-12 parts of smoked plum, 4-8 parts of radix saposhnikoviae, 8-12 parts of schisandra chinensis, 4-8 parts of radix pseudostellariae, 13-17 parts of rhizoma phragmitis and 13-17 parts of cogongrass rhizome; the medicine is beneficial to improving immunity, clearing heat, removing toxicity, clearing throats, relieving a cough, resisting allergic and preventing recurrence, has good medicine flavor, and is convenient to drink. In a word, the formula is reasonable in compatibility of medicines and is an effective prescription for taking temporary solution and effecting a permanent cure as well as treating both principal and secondary aspects of cough variant asthma. Tests show that the effective rate is up to 96.7%, no dependency or rebound phenomenon caused by drug withdrawal are generated, the medicine not only can tonify the lung and benefit qi as well as relieve a cough and asthma, but also can resist allergy and prevent recurrence, and compared with therapy by western medicines, the medicine provided by the invention has certain advantages.
Owner:江苏叠石桥家纺产业集团有限公司
Method for the treatment of cancer
InactiveUS20110014303A1Inhibit continued growthAvoid recoveryBiocideOrganic active ingredientsDrug withdrawalLymphatic Spread
The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
Owner:UNIV COLLEGE CORK NAT UNIV OF IRELAND CORK
Alpha-CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ActiveUS20150299276A1Potent activityBacteriaPeptide/protein ingredientsDrug withdrawalAlpha-Conotoxin
The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide. The present invention discloses a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The α-conotoxin peptide of the present invention can specifically block acetylcholine receptor (nAChRs, such as α3β2 nAChRs, α6 / α3β2β3 nAChR or α3β4 nAChR or α6 / α3β4 nAChR), has activity for treatment of neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, cancers, and can be used in the manufacture of a medicament for analgesia and smoking cessation and drug-withdrawal, a medicament for treatment of mental diseases and cancers, as well as a tool drug for neurosciences.
Owner:HAINAN UNIVERSITY
Intestinal flora capsule for treating methylamphetamine addiction withdrawal and preparation method
InactiveCN110292585ANon-toxicNo long-term effectivenessNervous disorderBacteria material medical ingredientsCross-linkFeces
Owner:SOUTHWEST UNIVERSITY
Procedure for screening of neuroactive substance and the associated neural plasticity
InactiveUS20050144654A1Simple and inexpensive and rapid methodRapid and simple and inexpensiveCompounds screening/testingBiological testingDrug withdrawalNeuroactive substances
The invention relates to a procedure for screening of neuroactive substance and the associated neural plasticity by treating fruitfly Drosophila melanogaster adult males with fly medium containing either of the neuroactive compounds strychnine, pentylenetetrazol, pilocarpine hydrochloride, tetraethylammonium chloride, lithium carbonate and ethosuximide, subjecting flies to negative geotaxis and horizontal locomotor assays, observing the height climbed and distance walked by and the climbing speed of the flies wherein an altered height climbed by flies under drug treatment and a long-lasting alteration in climbing speed of flies after drug withdrawal is most characteristic of the neuractive compounds.
Owner:COUNCIL OF SCI & IND RES
Anti-hypertension tea bag
InactiveCN104904909AGood curative effectQuick resultsPre-extraction tea treatmentCardiovascular disorderSide effectDrug withdrawal
The invention discloses an anti-hypertension tea bag, belonging to the technical field of traditional Chinese medicine for health care. The anti-hypertension tea bag is prepared from the following raw materials in parts by weight: 15-25 parts of green tea, 5-15 parts of semen cassiae, 10-20 parts of arabian jasmine flower, 10-20 parts of sophora flowers, 10-20 parts of chrysanthemum flowers, 5-15 parts of polygonum multiflorum, 5-15 parts of radix bupleuri, 5-15 parts of dandelion, 5-15 parts of radix rehmanniae recen and 5-15 parts of fruits of wolfberries. According to the anti-hypertension tea bag, the green tea is taken as the main raw material and is matched with an approximate amount of Chinese medicines, so that inducement causing hypertension is eliminated, the anti-hypertension tea bag has the effects of softening blood vessels, regulating blood lipids, reducing blood viscosity and the like, the defects of the traditional medicines that blood pressure is reduced only through blood vessel expanding, rebounding occurs after drug withdrawal, and the side effects are serious, are overcome. By frequently taking the health tea, blood pressure can be stably and continuously reduced, and the curative effect is good and quick, and lifelong medication is not needed. Symptoms including headache, insomnia and palpitation can be effectively eliminated, and hypertension can be completely cured and can not recur.
Owner:袁国防
Pharmaceutical composition using liensinine to work in coordination with paclitaxel for chemotherapy and application method of pharmaceutical composition
InactiveCN104586847AGood curative effectReduce adverse reactionsOrganic active ingredientsAntineoplastic agentsTreatment effectDrug withdrawal
The invention relates to a pharmaceutical composition using liensinine to work in coordination with paclitaxel for chemotherapy and an application method of the pharmaceutical composition. The pharmaceutical composition comprises a liensinine injection solution and a chemotherapy drug paclitaxel injection solution. The application method comprises the following steps: (1) performing intravenous injection of liensinine once daily according to the dose that actual dosage in the liensinine injection solution to the body weight of a patient is equal to 4.88mg / kg; (2) performing intravenous injection of paclitaxel once according to the dose that the actual dosage in the paclitaxel injection solution to the body weight of the patient is equal to 2.562mg / kg on the day of injecting liensinine according to the step (1); (3) performing intravenous injection of the paclitaxel injection solution once again according to the dose in the step (2) on the twenty-second day; and (4) determining whether to circulate according to the method of the steps (1)-(3) or not, the number of circulation times and the intermediate drug withdrawal time from the forty-third day according to the bearing capacity and the treatment effect of a patient body. Compared with the prior art, in the aspect of inhibiting and killing various malignant tumor cells, the pharmaceutical composition provided by the invention has the advantages of reducing the dosage, shortening the treatment period and reducing the occurrence of toxic and side reactions.
Owner:ARMY MEDICAL UNIV
Drug-addiction-stopping tea and preparation method thereof
InactiveCN103417896AEnhanced inhibitory effectImprove the immunityNervous disorderPre-extraction tea treatmentLower limitSide effect
The invention relates to a drug-addiction-stopping tea, and especially relates to a drug-addiction-stopping tea which has no toxic and side effects, and does not cause untoward effect, addiction and dependence. Tea leaves and traditional Chinese medicines are combined together, so that the drug-addiction-stopping tea of the invention has the special performance that 'medicines achieve the effects by means of the tea, and the tea achieves the effects by means of the medicines', belongs to a tea treasure usable as both food and medicine, and is capable of effectively reducing the relapse rate to a lowest limit or zero; and the drug-addiction-stopping tea has a high drug withdrawal rate, a low relapse rate, good curative effect and almost no toxic and side effects, does not cause untoward effect, addiction and dependence, and helps to comprehensively improve drug rehabilitation success rate.
Owner:DONGFANG YIKANG FUJIAN TECH DEV
Infusion control system and infusion system
InactiveCN109602974AStop the flowInfusion regulationFlow monitorsFlow controlElectricityDrug withdrawal
The invention relates to an infusion control system and an infusion system. The infusion control system comprises a drip rate detecting device, a drug withdrawal control device and a controller; the drip rate detecting device comprises a dual-beam photoelectric switch; the dual-beam photoelectric switch comprises a transmitter and a receiver; the transmitter and the receiver are in aligning arrangement on both sides of a drip path of a dripper; the drug withdrawal control device includes a motor and a pusher assembly; the pushing assembly is disposed on an adjustment star wheel of a flow regulator; the pushing assembly is in driving connection to the motor; the pushing assembly is used to push the star wheel to move under the drive of the motor; the controller is electrically connected tothe transmitter and the receiver; and the controller is also electrically connected to the motor. When the infusion control system is applied to an infusion device, the infusion can be automatically stopped after the liquid in an infusion bottle is emptied, thereby avoiding the problem of returning blood of a patient and cause of unnecessary loss and pain, and improving the safety of the infusion.
Owner:HUAIHUA UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com